
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the optimal use of cabazitaxel for the treatment of prostate cancer.
Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the optimal use of cabazitaxel for the treatment of prostate cancer.






